Thus, administration of type I IFNs (IFN-α, IFN-β) is considered a treatment strategy in cancer (275) as they facilitate DC activation, migration, and cross-presentation, thus enhancing the DC anti-tumor immunity (276). This evidence concerns the gene IFNB1 and cancer.